|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8510 EUR | -2.18% |
|
-3.08% | -27.76% |
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
Other Revenues, Total | 39 | 22 | 200K | 46 | 188 | |
Total Revenues | 39 | 22 | 200K | 46 | 188 | |
Cost of Goods Sold, Total | 531K | 2.24M | 3.48M | 1.55M | 2.52M | |
Gross Profit | -531K | -2.24M | -3.28M | -1.55M | -2.52M | |
Selling General & Admin Expenses, Total | 278K | 722K | 775K | 1.07M | 1.18M | |
Depreciation & Amortization - (IS) | 43.5K | 52.44K | 56.06K | 67.14K | 86.4K | |
Other Operating Expenses | 49.79K | 73.15K | 122K | 105K | 82.55K | |
Other Operating Expenses, Total | 371K | 847K | 953K | 1.24M | 1.35M | |
Operating Income | -902K | -3.08M | -4.23M | -2.79M | -3.87M | |
Interest Expense, Total | -538 | -493 | -6.51K | -304 | -14.19K | |
Interest And Investment Income | 527 | - | 94.86K | 67.29K | 31.18K | |
Net Interest Expenses | -11 | -493 | 88.36K | 66.99K | 16.99K | |
Currency Exchange Gains (Loss) | - | 4.84K | -395 | -1.7K | -2.11K | |
Other Non Operating Income (Expenses) | -218K | 178K | 30.59K | 8.56K | - | |
EBT, Excl. Unusual Items | -1.12M | -2.9M | -4.11M | -2.72M | -3.86M | |
Other Unusual Items | - | 39.02K | - | - | - | |
EBT, Incl. Unusual Items | -1.12M | -2.86M | -4.11M | -2.72M | -3.86M | |
Income Tax Expense | -141K | -418K | -366K | -635K | -540K | |
Earnings From Continuing Operations | -978K | -2.44M | -3.75M | -2.08M | -3.32M | |
Net Income to Company | -978K | -2.44M | -3.75M | -2.08M | -3.32M | |
Net Income - (IS) | -978K | -2.44M | -3.75M | -2.08M | -3.32M | |
Net Income to Common Incl Extra Items | -978K | -2.44M | -3.75M | -2.08M | -3.32M | |
Net Income to Common Excl. Extra Items | -978K | -2.44M | -3.75M | -2.08M | -3.32M | |
Per Share Items | ||||||
Net EPS - Basic | -0.19 | -0.47 | -0.46 | -0.21 | -0.26 | |
Basic EPS - Continuing Operations | -0.19 | -0.47 | -0.46 | -0.21 | -0.26 | |
Basic Weighted Average Shares Outstanding | 5.23M | 5.23M | 8.16M | 10.1M | 13.01M | |
Net EPS - Diluted | -0.19 | -0.47 | -0.46 | -0.21 | -0.26 | |
Diluted EPS - Continuing Operations | -0.19 | -0.47 | -0.46 | -0.21 | -0.26 | |
Diluted Weighted Average Shares Outstanding | 5.23M | 5.23M | 8.16M | 10.1M | 13.01M | |
Normalized Basic EPS | -0.13 | -0.35 | -0.31 | -0.17 | -0.19 | |
Normalized Diluted EPS | -0.13 | -0.35 | -0.31 | -0.17 | -0.19 | |
Supplemental Items | ||||||
EBITDA | -858K | -3.03M | -4.17M | -2.72M | -3.79M | |
EBITA | -902K | -3.08M | -4.23M | -2.79M | -3.87M | |
EBIT | -902K | -3.08M | -4.23M | -2.79M | -3.87M | |
Total Revenues (As Reported) | 39 | 22 | 200K | 46 | 188 | |
Effective Tax Rate - (Ratio) | 12.62 | 14.6 | 8.91 | 23.39 | 13.99 | |
Normalized Net Income | -700K | -1.81M | -2.57M | -1.7M | -2.41M |
- Stock Market
- Stocks
- ALNFL Stock
- Financials NFL Biosciences
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















